Bloomberg Law
How Life Sciences Firms Can Reduce DOJ Enforcement Risks
May 6, 2021
The Anti-Kickback Statute has long been a driver of enforcement actions against the life sciences industry. In this article, Sidley lawyers explore areas that are most likely to draw enforcement scrutiny and how compliance programs can be updated to control risk going forward.
連絡先
関連公式ブログ
得意分野
Suggested News & Insights
Sidley Highly Ranked in Chambers USA 2026June 4, 2026DOJ’s Civil Rights Fraud Initiative Raises False Claims Act Risks for Healthcare and Life Sciences CompaniesJune 4, 2026DOJ Announces Accelerated Review of FCA Qui Tams Alleging Fraud Against State-Administered Benefits ProgramsMay 28, 2026Sidley Lawyers Jaime Jones, Jennifer Saulino, and Lisa Miller to Speak at the ABA′s 2026 Qui Tam & Civil False Claims and Healthcare Fraud Institute in Washington, D.C.Wednesday, May 27, 2026 – Thursday, May 28, 2026DOJ and Texas AG Announce First Settlement in National Investigation of Gender-Affirming Care for MinorsMay 26, 2026Vice President and CMS Announce Suite of New Administrative Actions to Further Federal Anti-Fraud Health Care InitiativesMay 20, 2026
- Stay Up To DateSubscribe to Sidley Publications
- Follow Sidley on Social MediaSocial Media Directory